Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04587687 · ClinicalTrials.gov registry record · Phase 2

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

A Phase 2 study of Recurrent Follicular Lymphoma and Refractory Follicular Lymphoma, sponsored by Joseph Tuscano.

Recruiting
Registry status
Phase 2
Development phase
23
Enrollment target
1
Study location

NCT04587687 is a Phase 2 study of Recurrent Follicular Lymphoma and Refractory Follicular Lymphoma that is actively recruiting participants, run by Joseph Tuscano. The registered enrollment target is 23 participants, below the 32-participant average among 20 other Recurrent Follicular Lymphoma trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04587687, a Phase 2 study of Recurrent Follicular Lymphoma and Refractory Follicular Lymphoma, is actively recruiting participants, sponsored by Joseph Tuscano.

RECRUITING
Registry status
Phase 2
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to determine if the combination of brentuximab vedotin plus bendamustine is safe and to determine the effectiveness of the combination.

Conditions Studied

Recurrent Follicular Lymphoma Refractory Follicular Lymphoma

Interventions

  • DRUG Brentuximab Vedotin
  • DRUG Bendamustine Hydrochloride

Study Locations (1)

California

  • University of California Davis Comprehensive Cancer Center - Sacramento

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2020-12-04
Est. Completion 2026-12
Phase Phase 2

Sponsor

Joseph Tuscano

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04587687

The ClinicalTrials.gov registry entry for NCT04587687 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 32-participant average among 20 other Recurrent Follicular Lymphoma trials with a reported enrollment target (28% lower). The listed sponsor is Joseph Tuscano, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Recurrent Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Brentuximab Vedotin is the first listed.

NCT04587687 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04587687 about?

NCT04587687 is a clinical study titled "Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma". This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called ved...

What is the current status of trial NCT04587687?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2020-12-04. Estimated completion is 2026-12.

What conditions does trial NCT04587687 study?

This clinical trial studies the following conditions: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma.

What interventions are being tested in trial NCT04587687?

The interventions under investigation include: Brentuximab Vedotin (DRUG), Bendamustine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT04587687?

This trial is sponsored by Joseph Tuscano, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04587687 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Follicular Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Follicular Lymphoma

All registered trials for this condition

Refractory Follicular Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.